Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 10:13:820724.
doi: 10.3389/fphar.2022.820724. eCollection 2022.

Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review

Einar S Björnsson  1   2 , Vesna Vucic  3 , Guido Stirnimann  4 , Mercedes Robles-Díaz  5
Affiliations
Review

Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review

Einar S Björnsson et al. Front Pharmacol. .

Abstract

Introduction: Apart from cessation of the implicated agent leading to drug-induced liver injury (DILI), there is no standard therapy for DILI. Corticosteroids have been used in DILI, although their efficacy is unclear. Published data showed either beneficial effects or no improvement associated with steroid therapy. The aim of the current study was to perform a systematic review of the role of corticosteroids in the treatment of DILI. Methods: A search was performed in PubMed, searching for the terms: "corticosteroids" and "drug-induced liver injury". Observation studies were included, but case reports excluded. Results: A total of 24 papers were retrieved. Most of these were observational studies on the effects of corticosteroids in moderate/severe DILI (n = 8), reports on the corticosteroid treatment in patients with drug-induced autoimmune hepatitis (DI-AIH) (n = 5), and effects of corticosteroids in drug-induced fulminant acute liver failure (ALF, n = 2). Furthermore, treatment of corticosteroids in patients with liver injury due to check point inhibitors (CPIs) was addressed in nine studies. In moderate/severe DILI, six out of eight studies suggested steroid treatment to be beneficial, whereas two studies showed negative results. All five observational studies on the effects of corticosteroids in DI-AIH showed good therapeutic response with rapid and long lasting effects after discontinuation of corticosteroids and without evidence of relapse. Steroid therapy was not associated with improved overall survival in patients with drug-induced fulminant ALF. CPIs-induced liver injury was found to improve spontaneously in 33-50% without corticosteroids, and the rate of patients who were treated responded to steroids in 33-100% (mean 72%). Conclusions: The majority of studies analyzing the effects of corticosteroids in moderate/severe DILI have demonstrated beneficial effects. However, this was not the case in drug-induced fulminant ALF. Patients with DI-AIH had an excellent response to corticosteroids. The majority of those with CPIs-induced liver injury responded to corticosteroids; however, patients without treatment usually recovered spontaneously. The observational design and comparison with historical controls in these studies makes it very difficult to draw conclusions on the efficacy of corticosteroids in DILI. Therefore, there is a strong need for a randomized controlled trial to properly assess the role of corticosteroids in DILI.

Keywords: DILI; acute liver failure; check point inhibitors; corticosteroids; drug-induced autoimmune hepatitis; drug-induced liver injury; treatment of DILI.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flow chart over the literature review process.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bernal W., Ma Y., Smith H. M., Portmann B., Wendon J., Vergani D. (2007). The Significance of Autoantibodies and Immunoglobulins in Acute Liver Failure: a Cohort Study. J. Hepatol. 47 (5), 664–670. 10.1016/j.jhep.2007.05.011 - DOI - PubMed
    1. Björnsson E., Jerlstad P., Bergqvist A., Olsson R. (2005). Fulminant Drug-Induced Hepatic Failure Leading to Death or Liver Transplantation in Sweden. Scand. J. Gastroenterol. 40 (9), 1095–1101. 10.1080/00365520510023846 - DOI - PubMed
    1. Björnsson E., Talwalkar J., Treeprasertsuk S., Kamath P. S., Takahashi N., Sanderson S., et al. (2010). Drug-Induced Autoimmune Hepatitis: Clinical Characteristics and Prognosis. Hepatology 51 (6), 2040–2048. 10.1002/hep.23588 - DOI - PubMed
    1. Björnsson E. S., Gunnarsson B. I., Gröndal G., Jonasson J. G., Einarsdottir R., Ludviksson B. R., et al. (2015). Risk of Drug-Induced Liver Injury from Tumor Necrosis Factor Antagonists. Clin. Gastroenterol. Hepatol. 13 (3), 602–608. 10.1016/j.cgh.2014.07.062 - DOI - PubMed
    1. Björnsson E. S., Bergmann O., Jonasson J. G., Grondal G., Gudbjornsson B., Olafsson S. (2017). Drug-induced Autoimmune Hepatitis: Response to Corticosteroids and Lack of Relapse after Cessation of Steroids. Clin. Gastroenterol. Hepatol. 15 (10), 1635–1636. 10.1016/j.cgh.2017.05.027 - DOI - PubMed